IMMUNOHISTOCHEMISTRY, MUM1

The IHC – MUM1 (Multiple Myeloma Oncogene 1) test is an immunohistochemistry-based diagnostic assay used to detect MUM1 protein expression in tissue samples. MUM1, also known as Interferon Regulatory Factor 4 (IRF4), is a nuclear transcription factor involved in the development and differentiation of B lymphocytes, plasma cells, and activated T cells.

This test is widely used in hematopathology to diagnose and classify lymphomas, plasma cell neoplasms, and other hematological malignancies. MUM1 expression is particularly important in identifying plasma cell differentiation and distinguishing specific subtypes of diffuse large B-cell lymphoma (DLBCL).

The IHC MUM1 test helps pathologists evaluate the cellular origin of tumors and classify lymphoid malignancies more accurately. It is often included in immunohistochemistry panels used for lymphoma diagnosis and prognostic assessment.

Benefits of the Test

• Helps diagnose lymphoma and plasma cell tumors
• Assists in classification of diffuse large B-cell lymphoma
• Supports identification of plasma cell differentiation
• Improves diagnostic accuracy in hematological malignancies
• Helps guide treatment planning and prognosis evaluation

Why Doctors Recommend This Test

Doctors recommend the IHC MUM1 test when evaluating lymphoid and plasma cell neoplasms. It is commonly used in:

• Diffuse large B-cell lymphoma (DLBCL) classification
• Multiple myeloma evaluation
• Plasma cell neoplasm diagnosis
• Lymph node biopsy assessment
• Hematopathology investigations
• Tumor immunophenotyping studies

MUM1 is frequently used alongside markers such as CD20, CD79a, BCL6, CD10, Ki-67, CD138, and PAX5 to provide comprehensive lymphoma and plasma cell tumor profiling.

Preparation Before Test

No special preparation is required for this test. Important considerations include:

• The test is performed on a biopsy, bone marrow, or surgical tissue sample
• No fasting is required
• No medication restrictions are generally necessary
• Clinical history and previous pathology findings may assist interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

• Patients with suspected lymphoma
• Individuals with enlarged lymph nodes requiring evaluation
• Patients with suspected multiple myeloma
• Cases requiring lymphoma subtype classification
• Oncology and hematology patients requiring immunohistochemistry profiling

The IHC MUM1 test is an important diagnostic tool in hematopathology. By identifying MUM1 protein expression, it helps clinicians accurately classify lymphoid and plasma cell malignancies and develop appropriate treatment strategies.

Clinical Significance

MUM1 immunostaining is commonly used in the evaluation of:

• Diffuse large B-cell lymphoma (DLBCL)
• Multiple myeloma
• Plasma cell neoplasms
• Hodgkin lymphoma
• Activated B-cell lymphomas
• Lymphoproliferative disorders

MUM1 positivity often indicates late-stage B-cell differentiation and plasma cell lineage, making it a valuable marker in lymphoma classification.